Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II α

Gene

Volumn 272, Issue 1-2, 2001, Pages 141-148

  Okada, Yoshito ^a   Tosaka, Aki ^a   Nimura, Yuji ^a   Kikuchi, Akihiko ^a   Yoshida, Shonen ^a   Suzuki, Motoshi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atypical MDR; Cancer; Chemotherapy; DNA replication; Genetic instability

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; DEOXYRIBONUCLEIC ACID TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CLEAVAGE; DRUG ACCUMULATION; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; MULTIDRUG RESISTANCE; MUTANT; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TEMPERATURE; YEAST CELL;

AMINO ACID SUBSTITUTION; AMSACRINE; ANTIGENS, NEOPLASM; CATALYSIS; DNA; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, SUPERHELICAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HUMANS; ISOENZYMES; MUTATION; PHENOTYPE; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 0035845016     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(01)00554-6     Document Type: Article

References (29)

1. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection
2. Structure and mechanism of DNA topoisomerase II
3. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide
4. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
5. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme
6. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells
7. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer
8. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine
9. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies
10. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors
11. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine
12. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin
13. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
14. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: Identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide
15. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity
16. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines
17. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities
18. Assignment of functional amino acids around the active site of human DNA topoisomerase IIalpha
19. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line
20. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: Implications for the mechanisms of doxorubicin action and cytotoxicity
21. DNA gyrase: Structure and function
22. A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP
23. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions
24. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas
25. Molecular cloning of partial cDNAs for rat DNA topoisomerase II isoforms and their differential expression in brain development
26. DNA topoisomerase II mutations and resistance to anti-tumor drugs
27. DNA topoisomerases
28. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex
29. Immunohistochemical study of DNA topoisomerase II in human gastric disorders